Site content: Global

Press Release

New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium

Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients Bologna, Italy and Huntingdon Valley, Pa., NOVEMBER 29, 2018 --...

Single-Cell Genomic Analysis of Blood Cancers to be Highlighted at American Society of Hematology Meeting

DEPArray Technology Used for Detection and Isolation of Lymphoma and Multiple Myeloma Cells Bologna, Italy and Huntingdon Valley, Pa., NOVEMBER 27, 2018 -- Menarini Silicon Biosystems...

Circulating Tumor Cells to Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., May 30, 2018 -- Menarini Silicon Biosystems announced today that a new study has found that using circulating...

Menarini Hires Their 17,000th Employee

The 17,000th employee in Menarini is Lara, 28 years old, a young graduate in Chemistry and Pharmaceutical Technology from the University of Florence, who is now employed...

A robust method to study cancer heterogeneity in liquid biopsy

Copy Number Alteration Profiling of Single Circulating Tumor Cells which May Be used to Predict Response to Therapy   Scientists reported the development of a robust and...

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington   WASHINGTON, D.C., May 11, 2017 – Cancer experts from around the world will...

Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets

Liquid Biopsy Test for Circulating Tumor Cells Marks Its First Entry into U.S. Diagnostics Market BOLOGNA, Italy, and Philadelphia, PA, April 3, 2017 – Menarini-Silicon...

Menarini-Silicon Biosystems to Acquire CELLSEARCH® CTC System

Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics Bologna, Italy and San Diego, CA, Dec 20, 2016 - Menarini-Silicon Biosystems today announced they have...

DEPArray™ Single-Cell Isolation Technology Enables Researchers to Develop a Model for Predicting Response to Treatment in Patients with Lung Cancer

Genetic Profiles of Circulating Tumor Cells May Predict Drug Resistance and Clinical Outcomes   BOLOGNA, Italy, and SAN DIEGO, Calif., November 25, 2016 –...
12345678